Oracle today announced the availability of Oracle® Health Sciences Central Coding Release 3.0. The third generation of the Web-based clinical trial data coding and dictionary management application includes expanded query management and automated workflows that help clinical trial sponsors and contract research organizations (CROs) improve the efficiency and consistency of the coding process.
Oracle Health Sciences Central Coding Release 3.0 features enhanced integration with Oracle Health Sciences InForm Global Trial Management Global Trial Management system, which promotes greater productivity via improved query management and workflow. This release enables users to create and manage Oracle Health Sciences InForm Global Trial Management queries directly in Oracle Health Sciences Central Coding Release 3.0, streamlining the coding process with one point of entry to apply and manage coding updates to all Oracle Health Sciences InForm Global Trial Management-managed trials in process.
It features:
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.